Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
| ▸ | PELI1 | Q96FA3 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13681548 | 0.89 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL13681515 | 0.81 | PELI1 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL30317489 | 0.80 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL14926735 | 0.80 | PELI1 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL3690722 | 0.79 | CYP3A4 (0.74) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL3453700 | 0.79 | CYP3A4 (0.74) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL19187446 | 0.78 | PELI1 (0.45) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL7992781 | 0.78 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL7992782 | 0.78 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL25673390 | 0.77 | PELI1 (0.57) | CYP3A4PELI1PTGS1ALOX5TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668011-B1 | HIV REPLICATION INHIBITING PURINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| US-7585861-B2 | HIV replication inhibitors; for (multi)drug resistant HIV infection | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-08 | — | — | US | disclosed |
| US-7585861-B2 | HIV replication inhibitors; for (multi)drug resistant HIV infection | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-08 | — | — | US | disclosed |
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | BMO BANK N.A., AS ADMINISTRATIVE AGENT | 2007-02-15 | — | — | US | disclosed |
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | BMO BANK N.A., AS ADMINISTRATIVE AGENT | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | REV1, CCNI, MCM6 | CYP1A2 2210/4885CYP3A4 930/4885CYP2D6 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.